OTC Watch

All stocks / RAPH

Raphael Pharmaceutical Inc. RAPH

Raphael Pharmaceutical (RAPH): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQBIsrael
Live quote on OTC Markets

Market listing

Full name
RAPHAEL PHARMACEUTICAL INC
Market tier
OTCQB
Trading status
Active
Last trade
Oct 16
Source: Stockwatch, 2026-11-17

News headlines

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
2025-11-17 12:03 ยท News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($1,279,000)
What it means

It spends more than it earns

Under strain

The company lost $1.3 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$45,000
Net cash used in operating activities
($210,000)
What it means

The cash could run out soon

Under strain

It had $45,000 in the bank and used about $17,500 a month. At that pace the money lasts about 3 months unless it borrows or sells more shares.

The report says
Total assets
$53,000
Total liabilities
$1,486,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $53,000. Its debts and unpaid bills add up to $1.5 million. That is about $28.04 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-08-14

Estimated float about 18,827,418 shares as of 2026-08-14: 20,176,418 outstanding minus 1,349,000 held by 1 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-08-12
19.6M
2025-09-30
19.6M
2025-11-13
19.6M
2025-12-31
20.2M
2026-03-31
20.2M
2026-05-14
20.2M
2026-06-30
20.2M
2026-08-14
20.2M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-09-01 8-KCURRENT REPORT
2026-08-14 10-QQUARTERLY REPORT
2026-07-17 8-KCURRENT REPORT
2026-05-14 10-QQUARTERLY REPORT
2026-04-06 4
2026-03-31 10-KANNUAL REPORT
2026-03-24 8-KCURRENT REPORT

Common questions about RAPH

Does RAPH file reports with the SEC?

Yes. Raphael Pharmaceutical files with the SEC under company number 0001415397. The most recent filing we hold is a 8-K dated 2026-09-01.

Source record

How many RAPH shares are outstanding?

20,176,418 shares as of 2026-08-14, as reported to the SEC.

Source record

Has RAPH filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Raphael Pharmaceutical?

Officers named in its insider filings: Hayon Igal Louria (Chief Technology Officer).

Source record

Is Raphael Pharmaceutical making money?

The company lost $1.3 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record